Sharemaestro Newsreel

Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed?

Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, …

Pfizer (PFE) Agreed To A $44 Million Chantix Settlement

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. …

How AstraZeneca’s $400bn deal unravelled

One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. …

One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses

Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was …

HCA’s New Clinical and Ambulatory Structure: Strategic Tune-Up or Turning Point for HCA (HCA)?

HCA Healthcare has appointed Michael Schlosser, M.D., as executive vice president and chief clinical officer and created a new Ambulatory Operations Group led by Charles Gressle, consolidating oversight of clinical services, digital transformation, and more than 2,700 outpatient facilities as part of a broad …

Is United Health Stock Still Undervalued?

The management team deserves credit for the adjustments made at the beginning of this year. Missed Nvidia in 2009? This Rare Signal Is Flashing Again.In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that …

1 Profitable Stock with Impressive Fundamentals and 2 We Avoid

1 Profitable Stock with Impressive Fundamentals and 2 We Avoid While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, "Your margin is my opportunity". Profits are …

Does Medtronic (MDT) Still Trade At A Discount After Its CE Mark Win?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic stock has delivered a 20.8% gain over the past three years, yet current checks suggest it now sits close to its estimated …

1 Profitable Stock with Impressive Fundamentals and 2 We Turn Down

1 Profitable Stock with Impressive Fundamentals and 2 We Turn Down While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, "Your margin is my opportunity". Not …

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q2 Earnings Call Vertex Pharmaceuticals' second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue …

technotrans SE (WBO:TTR1) (Q2 2026) Earnings Call Highlights: Margin Resilience and Strategic ...

This article first appeared on GuruFocus. Revenue: EUR113.3 million in H1 2026, down 6% from EUR120.6 million in the prior year. EBIT: EUR8.0 million in H1 2026, compared to EUR8.4 million one year ago. EBIT Margin: Increased to 7.1% from 7.0% in the prior …

¿Puede Abbott Laboratories (ABT) Estar 8% Infravalorada Tras Mejorar Su Previsión Anual?

AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision …

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Nebius Group N.V. (NBIS [https://seekingalpha.com/symbol/NBIS]) * Tencent Holdings Limited (TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Brinker International (EAT [https://seekingalpha.com/symbol/EAT]) * Amcor plc (AMCR [https://seekingalpha.com/symbol/AMCR]) * Jumia Technologies AG (JMIA [https://seekingalpha.com/symbol/JMIA]) Other earnings slated for release before Wednesday's …

Stryker’s (SYK) Comeback Quarter Looks Great, But At What Cost?

Stryker (NYSE:SYK) turned in one of its stronger quarters in recent memory on July 30, with sales climbing 9.4% to $6.6 billion and reported EPS jumping 44.1% to $3.30. The numbers arrive as the company works its way back from a cyber incident that …

Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)?

Thermo Fisher Scientific (NYSE:TMO) mostly sells the instruments and supplies that let other companies do science, not the treatments themselves. So when the company said on July 29 that it had launched the PPD CorEvitas Vitiligo Registry on July 14, to track how patients …

SBO Strengthens Position in 3D Metal Printing: Expanded Capacity in the US and the UK, Award for 3T

TERNITZ, AUSTRIA - August 11, 2026 (NEWMEDIAWIRE) - SBO AG, listed on the leading index ATX of the Vienna Stock Exchange, is expanding its 3D metal printing capacity in the US and the UK and strengthening its market position in Europe through an award …

AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in …

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

MacroGenics, Inc. ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license …

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci Corporation Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half …

Is Hims The Next Big Name In Peptides? Shares Topple Despite Sales Beat.

Hims stock toppled Tuesday. Analysts are watching the telehealth giant's move closer to the peptide segment. Continue Reading

AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk

AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the …

This Buffett Oil Stock Is Quietly Outperforming Chevron Under Greg Abel. Is It Worth Buying Now?

Key Points Occidental shares have soared by nearly 36% since Greg Abel became Berkshire Hathaway's CEO in January. Further gains hinge highly on a resurgence in crude oil prices, making Oxy a more binary bet than Chevron, another top Berkshire Hathaway oil stock holding. …

Medtronic (MDT) Wins Analyst Upgrades, Is It Fully Priced?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic (MDT) has moved back into focus after multiple analyst upgrades tied to what they describe as the company's strongest annual revenue growth …

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's …

Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. …

Jim Cramer Highlights Arista Networks (ANET) Following Q2 Beat and 50% Rally

Arista Networks, Inc. (NYSE:ANET) posted $3.04 billion in total sales for Q2 2026, which represents a 37.7% year-over-year increase and beat Wall Street consensus estimates by $210 million. Non-GAAP earnings per share came in at $1.02, topping expectations by $0.13. The top-line expansion pulled …

Arrow Exploration confirms four zones at Icaco 3, opens up ~10 new drilling locations

Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott tells Proactive's Stephen Gunnion that the Icaco 3 well has confirmed up to four hydrocarbon-bearing zones in the Icaco extension of the Tapir Block in Colombia, opening almost 10 additional development locations across the Ubaque, …

2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now

Space Exploration Technologies (NASDAQ: SPCX) has been perhaps the most talked-about stock on Wall Street since it completed the largest IPO ever in mid-June. Opinions on the company's prospects are divided. Some see an innovative company that has already disrupted the space travel industry …

Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down

Hims & Hers Health, Inc. HIMS reported quarterly adjusted loss per share of 10 cents in second-quarter 2026, against the year-ago period's adjusted earnings per share (EPS) of 17 cents. The metric was wider than the Zacks Consensus Estimate of loss per share of …

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% …

Jim Cramer Weighs In on Sentiment Shifts Driving Accenture and Cognizant Rallies

On Monday's CNBC Mad Money episode, host Jim Cramer examined the top-performing stocks in the S&P 500, focusing on the dramatic turnaround in IT consulting leaders Cognizant Technology Solutions Corporation (NASDAQ:CTSH) and Accenture plc (NYSE:ACN). Addressing how market sentiment shifted around the "AI displacement …

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

Quick Read LEGN surged 6% as Q2 revenue of $388M beat estimates and adjusted EPS of $0.16 doubled consensus, marking the company's first-ever profitable quarter. CARVYKTI net sales hit $657M, up 50%, with JNJ co-developer Janssen supporting management's target of over $5B in peak …

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BridgeBio Pharma BBIO reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents. Revenues surged 120% year over …

IDEXX (IDXX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Mike Erickson Chief Financial Officer - Andrew Emerson Vice President, Investor Relations - John Ravis Full Conference Call Transcript Operator: Good morning, …

CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up

Cardinal Health, Inc. CAH reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.91, beating the Zacks Consensus Estimate by 20.3%. The bottom line improved 40% year over year, aided by higher operating earnings, IEEPA tariff refunds, a lower tax rate and a …